Genmab's Humax-CD4 Shows Statistically Significant Dose Response In
This press release is transmitted on behalf of Genmab A/S San Francisco - Genmab A/S (CSE: GEN and Neuer Markt: GE9D) announced today that HuMax-CD4 has shown a statistically significant dose response in doses up to 160mg in initial results of a psoriasis Phase II dose finding study.
In addition, mean Psoriasis Area Severity Index (PASI) score was reduced in all treatment groups with a 30% difference between the placebo and 160mg dose groups.
HuMax-CD4 was also safe and well tolerated.
These initial results are based on data at the seven-week timepoint from 79 of 85 patients in the Phase II study and are being presented today by Genmab's Chief Scientific Officer Jan van de Winkel, Ph.D.
at the 65th Annual Meeting of the American College of Rheumatology in San Francisco, California.
This psoriasis trial is a small placebo controlled Phase II study designed to establish the safety and lowest effective dose of HuMax-CD4 in patients with moderate to severe psoriasis.
Patients received either one of four dose levels or placebo once weekly for four weeks.
They are being followed for a total of 16 weeks, and final results of the study will not be available until next year.
The dose response observed here correlates with the results of the HuMax- CD4 Phase I/II study in RA patients, where half the patients receiving doses of above approximately 35mg achieved ACR-20.
"These results are very encouraging," said Lisa N.
Drakeman, Ph.D., Chief Executive Officer.
"The biological effect of HuMax-CD4 seen in the Phase I/II study is confirmed here.
I look forward to the ongoing development of this promising antibody." About Genmab A/S Genmab A/S is a biotechnology company that creates and develops fully human antibodies for the treatment of life-threatening and debilitating diseases.
Genmab has numerous products in development to treat cancer, rheumatoid arthritis and other inflammatory conditions, and intends to assemble a broad portfolio of new therapeutic products arising from research into the human genome.
At present, Genmab's commercial opportunities are based upon research conducted at leading international companies, including Roche, Immunex Corporation, Oxford GlycoSciences (LSE: OGS.L - news) Ltd., Medarex, Inc., deCODE Genetics, Scancell, Ltd., Sequenom, Inc., Eos Biotechnology Inc., and Glaucus Proteomics B.V., as well as in its own laboratories.
A broad alliance provides Genmab with access to Medarex Inc.'s array of proprietary technologies, including the UltiMAb(TM) platform for the rapid creation and development of fully human antibodies to virtually any disease target.
For more information about Genmab, visit genmab.com |
